Instituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, Veracruz 91700, Mexico.
Departamento de Inmunología y Unidad de Investigación, Instituto de Oftalmología "Conde de Valencia", Ciudad de México 06800, Mexico.
Nutrients. 2022 Dec 8;14(24):5227. doi: 10.3390/nu14245227.
Irritable Bowel Syndrome (IBS) is usually a lifelong state that disturbs the digestive system. IBS has been linked to low-grade inflammation and the release of inflammatory mediators into the bloodstream. This could be associated with the degree of obesity presented by patients with IBS. Reports imply that IBS is more frequent in obese patients than in the overall population, with a prevalence of up to 31%. Here, we evaluated the serum levels of immunological and inflammation molecules and their correlation with Body Mass Index in IBS patients and the healthy control (HC). Seventy-nine serum samples of the IBS patients and thirty-five of the HC group were analyzed to determine the levels of each molecule and compare them with their BMI. Serum levels of C3 and C4 were significantly increased in IBS patients. C3 and C4 levels were higher in IBS-M and IBS-D subtypes compared with the HC group. When patients were grouped by BMI, a positive correlation between serum C3 (r = 0.49, p < 0.0001) and CRP (r = 0.40, p < 0.001) levels was found. Our results show, for the first time, a correlation between immunological molecules and BMI in IBS patients, suggesting that the inflammatory nature of obesity could contribute to the development of the symptoms in IBS through the stimulation and release of proteins as complement components and CRP.
肠易激综合征(IBS)通常是一种扰乱消化系统的终身状态。IBS 与低度炎症和炎症介质释放到血液中有关。这可能与 IBS 患者的肥胖程度有关。报告表明,IBS 在肥胖患者中比在普通人群中更为常见,患病率高达 31%。在这里,我们评估了 IBS 患者和健康对照组(HC)的血清免疫和炎症分子水平及其与体重指数的相关性。分析了 79 例 IBS 患者和 35 例 HC 组的血清样本,以确定每种分子的水平并将其与 BMI 进行比较。IBS 患者的血清 C3 和 C4 水平显著升高。与 HC 组相比,IBS-M 和 IBS-D 亚型的 C3 和 C4 水平更高。当按 BMI 将患者分组时,发现血清 C3(r = 0.49,p < 0.0001)和 CRP(r = 0.40,p < 0.001)水平之间存在正相关。我们的研究结果首次表明,IBS 患者的免疫分子与 BMI 之间存在相关性,这表明肥胖的炎症性质可能通过刺激和释放补体成分和 CRP 等蛋白质来促进 IBS 症状的发展。